Loading...
Loading...
IDYA| Name | Value |
|---|---|
| Revenues | 3.5M |
| Cost of Revenue | 1.0M |
| Gross Profit | 2.5M |
| Operating Expense | 36.3M |
| Operating I/L | -32.7M |
| Other Income/Expense | 4.8M |
| Interest Income | 4.8M |
| Pretax | -27.9M |
| Income Tax Expense | -1.0M |
| Net Income/Loss | -27.9M |
IDEAYA Biosciences, Inc. is a precision medicine oncology company specializing in synthetic lethality-focused targeted therapeutics. Their lead product candidates, IDE397 and IDE196, are in clinical trials for specific solid tumors with genetic mutations. The company's preclinical pipeline includes programs targeting various genetic mutations and molecular signatures. IDEAYA has research collaborations and clinical trial agreements with Cancer Research UK, the University of Manchester, Pfizer Inc., and a strategic partnership with GlaxoSmithKline plc.
